Language selection

Government of Canada / Gouvernement du Canada

Search

Editorial: Engineering antibodies and bacteriophages to manage and diagnose microbial infections

From National Research Council Canada

Download
  1. (PDF, 245 KiB)
DOIResolve DOI: https://doi.org/10.3389/fmicb.2025.1567335
AuthorSearch for: 1ORCID identifier: https://orcid.org/0000-0002-5240-4598; Search for: ; Search for:
Affiliation
  1. National Research Council of Canada. Human Health Therapeutics
FormatText, Article
Subjectantibody engineering; bacteriophage engineering; antimicrobial treatment; diagnosis of microbial infections; antimicrobial resistance
Abstract
There is an urgent and growing need for novel and effective antimicrobial agents to combat the increasing number of pathogens resistant to multiple classes of antimicrobial chemotherapeutics. Exploring treatments and diagnostics for pathogens using the complementary strengths offered by antibodies and bacteriophages promises to provide novel solutions to meet the formidable challenges posed by emerging pathogens and well-known pathogens where resistance to antimicrobial chemotherapeutics is becoming a growing threat. These approaches build upon a broad and ever-expanding variety of antibody formats that include monoclonal antibodies, single-chain Fvs and single-domain antibodies, as well as diverse natural and engineered bacteriophages, chemical conjugates and phage-derived enzymes. This Research Topic focuses on studies that contribute to the exploration and development of some of the emerging tools based on antibodies and bacteriophages to manage and diagnose microbial infections.
Publication date
PublisherFrontiers Media
Licence
In
  • Frontiers in Microbiology 16 (17 February 2025): 1–2.
LanguageEnglish
Peer reviewedYes
Export citationExport as RIS
Report a correctionReport a correction (opens in a new tab)
Record identifieraa91c950-f1d2-4dad-b07e-c32fe9930f6c
Record created2025-06-16
Record modified2025-06-16
Date modified: